Triple drug therapy with GABA, sitagliptin, and omeprazole prevents type 1 diabetes onset and promotes its reversal in non-obese diabetic mice
Open Access
- 21 October 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 13, 1028114
Abstract
Previous studies have reported that dual drug combinations consisting of γ-aminobutyric acid (GABA) together with a dipeptidyl-peptidase-4 inhibitor (DPP-4i), also a DPP-4i with a proton pump inhibitor (PPI), could improve pancreatic β-cell function and ameliorate diabetes in diabetic mice. In this study, we sought to determine if a triple drug combination of GABA, a DPP-4i and a PPI might have superior therapeutic effects compared with double drug therapies in the prevention and reversal of diabetes in the non-obese diabetic (NOD) mouse model of human type 1 diabetes (T1D). In a diabetes prevention arm of the study, the triple drug combination of GABA, a DPP-4i, and a PPI exhibited superior therapeutic effects in preventing the onset of diabetes compared with all the double drug combinations and placebo. Also, the triple drug combination significantly increased circulating C-peptide and serum insulin levels in the mice. In a diabetes reversal arm of the study, the triple drug combination was superior to all of the double drug combinations in reducing hyperglycemia in the mice. In addition, the triple drug combination was the most effective in increasing circulating levels of C-peptide and serum insulin, thereby significantly reducing exogenous insulin needs. The combination of GABA, a DPP-4i and a PPI appears to be a promising and easily scalable therapy for the treatment and prevention of T1D.Keywords
Funding Information
- Vetenskapsrådet
- Novo Nordisk Fonden
This publication has 63 references indexed in Scilit:
- The clinical utility of C‐peptide measurement in the care of patients with diabetesDiabetic Medicine, 2013
- The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic miceJournal of Endocrinology, 2012
- Combination Therapy with a Dipeptidyl Peptidase-4 Inhibitor and a Proton Pump Inhibitor Induces β-Cell Neogenesis from Adult Human Pancreatic Duct Cells Implanted in Immunodeficient MiceCell Transplantation, 2011
- GABA exerts protective and regenerative effects on islet beta cells and reverses diabetesProceedings of the National Academy of Sciences, 2011
- The oral DPP‐4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitusDiabetes, Obesity and Metabolism, 2011
- Combining a dipeptidyl peptidase‐4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and β‐cell function in db/db miceBritish Journal of Pharmacology, 2009
- Animal models of human type 1 diabetesNature Immunology, 2009
- Effect of Vildagliptin on Glucagon Concentration During Meals in Patients with Type 1 DiabetesHormone and Metabolic Research, 2008
- Pharmacokinetics and Pharmacodynamics of Vildagliptin??in??Patients?? with Type??2??Diabetes??MellitusClinical Pharmacokinetics, 2007
- Utility of murine models for the study of spontaneous autoimmune type 1 diabetesPediatric Diabetes, 2005